EXPANDING THE REACH OF CANCER METABOLOMICS
Christian M. Metallo
 Perspect. on Montrose et al., p. 1358

DIFFLUOROMETHYLORNITHINE: THE PROOF IS IN THE POLYAMINES
Joanne M. Jeter and David S. Alberts
 Perspect. on Kreul et al., p. 1368

IS THERE A LINK BETWEEN GENOME-WIDE HYPMETHYLATION IN BLOOD AND CANCER RISK?
Kevin Brennan and James M. Flanagan

METHANOLICATION, A NONINVASIVE APPROACH FOR THE DETECTION OF EXPERIMENTAL COLORECTAL NEOPLASIA
David C. Montrose, Xi Kathy Zhou, Levy Kopelevich, Rhonda K. Yantiss, Edward D. Karoly, Kotha Subbaramaiah, and Andrew J. Dannenberg
 See Perspect. on p. 1337

A PHASE III SKIN CANCER CHEMOPREVENTION STUDY OF DFMO: LONG-TERM FOLLOW-UP OF SKIN CANCER EVENTS AND TOXICITY
Sarah M. Kreul, Tom Havighurst, KyungMann Kim, Eneida A. Mendonça, Gary S. Wood, Stephen Snow, Abbey Borich, Ajit Verma, and Howard H. Bailey
 See Perspect. on p. 1337

BENIGN BREAST DISEASE AND THE RISK OF SUBSEQUENT BREAST CANCER IN AFRICAN AMERICAN WOMEN
Michele L. Cote, Julie J. Rutelbusch, Bara Aloth, Sudeshna Bandypadhyay, Elizabeth Kim, Bassam Albashiti, Bashar Sharaf Aldeen, Derek C. Radisky, Marlene H. Frost, Daniel W. Visscher, Lynn C. Hartmann, Hind Nassar Warzecha, and Rouba Ali-Femhi

DESIGN AND BASELINE CHARACTERISTICS OF PARTICIPANTS IN A PHASE III RANDOMIZED TRIAL OF CELECOXIB AND SELENIUM FOR COLORECTAL ADENOMA PREVENTION

INHIBITION OF mTOR SUPPRESSES UVB-INDUCED KERATINOCYTE PROLIFERATION AND SURVIVAL
Theresa D. Carr, John DiGiovanni, Christopher J. Lynch, and Lisa M. Shantz

RISK STRATIFICATION FOR ADVANCED COLORECTAL NEOPLASIA—LETTER
Paula Berstad, Magnus Løberg, Mette Kalager, Anita Jørgensen, Kjetil Garborg, Hans Kristian Ruud, Michael Brethauer, and Geir Hoff

RISK STRATIFICATION FOR ADVANCED COLORECTAL NEOPLASIA—RESPONSE
Paul C. Schroy III

CORRECTION
Correction: Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal Neoplasia

ACKNOWLEDGMENT TO REVIEWERS
ABOUT THE COVER

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Although noninvasive fecal blood tests are widely used for the early detection of colorectal neoplasia, these tests have limited sensitivity and specificity. Metabolomics can be used to identify and quantify small molecules. In this study, metabolic profiling of feces was evaluated as a potential noninvasive approach to identify biomarkers of colorectal carcinogenesis. The cover image shows time-dependent effect size differences in metabolite levels in feces from colon tumor-bearing mice vs. healthy mice. Feces were analyzed three, five, and seven weeks following six weekly injections of azoxymethane, a colon carcinogen, or saline. The levels of fecal metabolites progressively change as tumor burden increases. Metabolomic profiling of feces represents a promising method to noninvasively detect colorectal tumors. See article by Montrose et al. (beginning on page 1358) for more information.